CEL-SCI (CVM) Stock Price, News & Analysis

Company Overview

CEL-SCI Corporation (NYSE:CVM) is a clinical-stage biotechnology company headquartered in Vienna, Virginia, dedicated to the development of novel immunotherapy products for cancer and infectious diseases. Founded in 1983, the company has built a research and development platform centered on stimulating the body’s own immune system to combat malignancies. With proprietary technologies in active clinical evaluation, CEL-SCI aims to address significant unmet medical needs through targeted immunomodulation.

The company’s lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is designed as a pre-surgical adjuvant for advanced head and neck cancer. Multikine works by activating key immune cell populations at the tumor site, and its pivotal Phase III trial is assessing efficacy on overall survival and disease progression. Alongside Multikine, CEL-SCI is advancing earlier-stage programs that leverage its immunotherapy platforms in both oncology and infectious disease settings.

Beyond Multikine, CEL-SCI’s pipeline includes the LEAPS (Ligand Epitope Antigen Presentation System) technology for autoimmune and infectious indications, and the VaxHit™ platform for rapid vaccine screening and development. These platforms reflect the company’s broader strategy of creating versatile immune-based treatments. CEL-SCI maintains research collaborations and proprietary manufacturing capabilities, with laboratory facilities in the United States and partnerships for clinical supply in Europe and Latin America.

Under the leadership of President and CEO Geert Kersten, CEL-SCI’s executive team and scientific advisory board comprise experts in oncology, immunology and clinical development. The company conducts multi-regional clinical programs and regulatory filings to bring its therapies to patients globally. With a focus on rigorous clinical design and strategic collaborations, CEL-SCI seeks to establish new standards in immunotherapy for challenging diseases.

Key Stats

• Today's Range: $3.95 to $4.16
• 50-Day Range: $2.10 to $7.77
• 52-Week Range: $1.98 to $66.60
• Volume: 417,623 shs
• Average Volume: 205,141 shs
• Market Capitalization: $12.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CEL-SCI Stock Analysis - MarketRank™

CEL-SCI scored higher than 3% of companies evaluated by MarketBeat, and ranked 927th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CEL-SCI.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CEL-SCI are expected to grow in the coming year, from ($0.29) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CEL-SCI is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CEL-SCI is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CEL-SCI has a P/B Ratio of 26.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.40% of the float of CEL-SCI has been sold short.

Short Interest Ratio / Days to Cover

CEL-SCI has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CEL-SCI has recently increased by 44.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CEL-SCI does not currently pay a dividend.

Dividend Growth

CEL-SCI does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.40% of the float of CEL-SCI has been sold short.

Short Interest Ratio / Days to Cover

CEL-SCI has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CEL-SCI has recently increased by 44.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

CEL-SCI has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for CEL-SCI this week, compared to 1 article on an average week.

Search Interest

10 people have searched for CVM on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CEL-SCI insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.93% of the stock of CEL-SCI is held by insiders.

Percentage Held by Institutions

Only 12.08% of the stock of CEL-SCI is held by institutions.

CVM Stock Analysis - Frequently Asked Questions

How have CVM shares performed this year?

CEL-SCI's stock was trading at $11.9970 at the beginning of 2025. Since then, CVM stock has decreased by 67.0% and is now trading at $3.96.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) posted its earnings results on Thursday, August, 15th. The company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($3.90) by $0.30.

When did CEL-SCI's stock split?

CEL-SCI shares reverse split on Thursday, June 15th 2017.The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of CEL-SCI?

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 7/18/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CVM
• CIK: 725363
• Web: cel-sci.com
• Phone: 703-506-9460
• Fax: 703-506-9471
• Employees: 43
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($12.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -238.05%
• Return on Assets: -104.65%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 1.07
• Quick Ratio: 1.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.15 per share
• Price / Book: 27.80

Miscellaneous

• Outstanding Shares: 3,032,000
• Free Float: 64,673,000
• Market Cap: $12.64 million
• Optionable: Optionable
• Beta: 0.30